<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063802</url>
  </required_header>
  <id_info>
    <org_study_id>DI/11/311/04/108</org_study_id>
    <nct_id>NCT02063802</nct_id>
  </id_info>
  <brief_title>Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese Children</brief_title>
  <official_title>Effect of an Intervention Program With Healthy Habits Plus Metformin or Conjugated Linoleic Acid Over Clinical Parameters and Molecular Pathways of Insulin Resistance in Obese Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to examine the effects of conjugated linoleic acid
      (CLA) vs metformin along with an intervention program with healthy habits on body
      composition, weight, M value in CLAMP and clinical laboratory values, as well as molecular
      and genetic changes in obese children.

      Patients from the pediatric service of the Hospital from 8 to 18 years old with a body mass
      index ≥ Pc 95 and 35kg/m2 are randomized to either interventional group for 4 months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in body mass index at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body fat mass at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lean body mass at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory values at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in M Value in CLAMP at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle tissue transcriptome at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in adipose tissue transcriptome at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory cytokines al 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the phosphorylation of the insulin receptor in muscle tissue at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the phosphorylation of the insulin receptor in adipocytes at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activation status of proteins involved in insulin signaling of myocytes cDNA at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>metformin and healthy habits program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gr per day. (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conjugated Linoleic Acid and healthy habits</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose: 3gr per day (500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner by mouth for four months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and healthy habits program</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.</description>
    <arm_group_label>metformin and healthy habits program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Conjugated Linoleic Acid</intervention_name>
    <description>total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.</description>
    <arm_group_label>Conjugated Linoleic Acid and healthy habits</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months</description>
    <arm_group_label>Placebo and healthy habits program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Healthy habits program</intervention_name>
    <arm_group_label>metformin and healthy habits program</arm_group_label>
    <arm_group_label>Conjugated Linoleic Acid and healthy habits</arm_group_label>
    <arm_group_label>Placebo and healthy habits program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes between 8 and 18 years old

          -  Pc BMI ≥ 95 and &lt;35kg/m2,

          -  No endocrine diseases, including diabetes mellitus

          -  No systemic diseases

          -  No genetic diseases

          -  No pharmacological treatment affecting lipid metabolism or glucose

          -  No history of acute or prolonged immobilization

          -  Normal aminotransferases

          -  Signed Informed consent and assent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nayely G Garibay, Pediatrician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gloria E Queipo, M.Specialist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge A Gonzalez, Director</last_name>
    <phone>521 (55)54883761</phone>
    <phone_ext>3761</phone_ext>
    <email>jogonzalez@silanes.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yulia Romero, Coordinator</last_name>
    <phone>521 (55)54883700</phone>
    <phone_ext>3777</phone_ext>
    <email>Yromero@silanes.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Mexico</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nayely G Garibay, Pediatrician</last_name>
      <phone>+52 (55) 59-48-26-37</phone>
      <email>gngaribay@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mayra A Bustos, Doctor</last_name>
      <phone>+52 7773406509</phone>
      <email>mayibe2609@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>February 13, 2014</last_update_submitted>
  <last_update_submitted_qc>February 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric obesity</keyword>
  <keyword>conjugated linoleic acid</keyword>
  <keyword>CLA</keyword>
  <keyword>metformin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 22, 2016</submitted>
    <returned>August 3, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

